Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.07 million to settle allegations that it violated the False Claims Act by failing to disclose research misconduct to federal agencies in grant applications and reports.
Bothell's Athira Pharma to pay $4M to settle falsified research claims
Bothell-based biopharmaceutical company Athira Pharma Inc. (Nasdaq: ATHA) is paying a $4.1 million fine due to allegations it used doctored research to land a National Institutes of Health grant.
Athira Pharma to Pay $4 Million in Settlement Over Research Misconduct Allegations
U.S. pharmaceutical company pays $4.07 million to resolve allegations that it violated the False Claims Act (FCA) by failing to report research misconduct allegations in grant applications.
Bothell's Athira Pharma Settles for Over $4 Million After Allegations of Research Misconduct
A biopharmaceutical company, Athira Pharma, settled for $4.068 million over allegations of research misconduct.
Athira Pharma to pay $4M to settle False Claims Act allegations
Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of
Bothell pharma company to pay $4 million over falsified research claims
A pharmaceutical company in Bothell has agreed to pay $4,068,698 to settle allegations it used falsified research to obtain grants from the National Institutes of Health (NIH), according to the Department of Justice.
Athira to pay $4M to resolve research misconduct allegations
Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. has agreed to pay more than $4 million to resolve False Claims Act allegations that it failed to report potential research misconduct to the NIH and the Department of Health and Human Services’ Office of Research Integrity in grant applications and progress reports.
Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares
CEO Mark James Litton sold 25,107 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $0.56, for a total transaction of $14,059.92. Following the ...
Medpage Today on MSN2d
Doc Accused of Sexually Exploiting Kids; More Women Accuse Ob/Gyn of Sex Assault
Florida physician Stephen Andrew Leedy, MD, has been accused of producing child sexual abuse materials and enticing minors to ...
Investing1mon
Athira Pharma's SWOT analysis: stock faces challenges after trial setback
Athira Pharma Inc. (NASDAQ:ATHA), a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, has experienced significant challenges in recent months. With a ...
CNN1y
Athira Pharma, Inc.
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.